MBRX - Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

• Moleculin Biotech ( NASDAQ: MBRX ) said preliminary data from the second group of its phase 1a study of WP1122 showed that the COVID-19 drug candidate was safe in healthy people.
• The second cohort consisted of 8 people who were dosed with 16 mg/kg or placebo in a dose escalation trial of WP1122 in healthy people in the U.K.
• The company said that based on the overall results in group 2, it deemed the cohort dose as safe and well-tolerated and began its Single Ascending Dose (SAD) group 3 with a dose escalation to 32 mg/kg.
• "To date, WP1122 has demonstrated no dose escalating stopping criteria, and we look forward to taking the next step in studying the potential of WP1122 for the treatment of certain viral diseases, including COVID-19, and cancers," said Moleculin Chairman and CEO Walter Klemp.
• The phase 1 trial in total is evaluating WP1122 administered as an oral solution.

For further details see: